Last updated 2026-07-26
- Acquired by Scipher Medicine Corporation for $150M, Jul 2026
- Acquired Anchiano Therapeutics, Mar 2021
- Raised Follow-on PO, Jul 2025
Total raised
—
Last: PIPE 2026-07
Stage
Acquired
Founded
2011
Headcount
12
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need. The company's lead candidate, nebokitug (CM-101), is a first-in-class dual activity monoclonal antibody that neutralizes CCL24, a soluble protein that plays a critical role in promoting fibrosis and inflammation. Nebokitug has demonstrated disease-modifying potential in clinical and preclinical studies and has a favorable safety profile, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.
Funding history · 7 rounds · — total
7 events/rounds · — Total Funding
Jul 2025
Follow-on PO
Undisclosed
Sep 2024
Follow-on PO
Undisclosed
Apr 2022
Follow-on PO
Undisclosed
Mar 2021
PIPE
Undisclosed
Feb 2021
Follow-on PO
Undisclosed
Feb 2019
Follow-on PO
Undisclosed
Jun 2012
IPO
Undisclosed
Acquisitions · 1
Mar 2021
Anchiano Therapeutics
Undisclosed
Headcount over time
12 employees (2026-09) · 1 point
Offices
Tel Aviv-Yafo, Israel · HQ / main office
Q&A
- What is Chemomab Therapeutics' primary focus?
- Chemomab Therapeutics is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.
- When was Chemomab Therapeutics founded?
- Chemomab Therapeutics was founded in September 2011.
- What is the status of Chemomab Therapeutics?
- Chemomab Therapeutics was acquired in July 2026.
- Who acquired Chemomab Therapeutics and for what amount?
- Chemomab Therapeutics was acquired by Scipher Medicine Corporation in July 2026 for $150,000,000.
- What was the most recent funding round for Chemomab Therapeutics before its acquisition?
- Chemomab Therapeutics completed a PIPE round in July 2026, raising $30,000,000.
- Which investors participated in Chemomab Therapeutics' B Round in December 2017?
- OrbiMed Israel and Peter Thiel participated in Chemomab Therapeutics' B Round in December 2017.
- How many employees does Chemomab Therapeutics have?
- Chemomab Therapeutics has 11-50 employees.
- What is Chemomab Therapeutics' lead candidate?
- Chemomab Therapeutics' lead candidate is nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24.
- What was Chemomab Therapeutics' first public offering amount and date?
- Chemomab Therapeutics' first public offering was in February 2019, raising $30,500,001.
Team · 17
Adi Mor
Founder · Co-Founder, CEO & Chief Scientific Officer
Jacob George
Founder · Scientific Co-Founder
Nissim Darvish
Chairman of the Board
Sigal Fattal
Chief Financial Officer
David M. Weiner
Interim Chief Medical Officer
Jack Lawler
Chief Development Officer
Revital Aricha
VP, Translational Science
Arun Sanyal
Scientific Advisor
Dinesh Khanna
Scientific Advisor
Francesco Del Galdo
Scientific Advisor
Marco Matucci-Cerinic
Scientific Advisor
Massimo Pinzani
Scientific Advisor
Scott L. Friedman
Scientific Advisor
Jill M. Quigley
Independent Director
Neil Cohen
Independent Director
Claude Nicaise
Independent Director
Alan C. Moses
Independent Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B
Highlights
Patents
Tags
pharmaceuticalsautoimmune-diseasesimmunologydrug-deliverydrug-discoveryhealthcare-providerstreatmentsantibodiesbiopharmaceuticalbiotechnologylife-sciencesfibrotic-diseasesinflammatory-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | chemomab.com |
|---|---|
| linkedin.com/company/18948873 |
Identifiers & details
| Legal name | Chemomab Therapeutics Ltd. |
|---|---|
| Founded | 2011-9 |
| Employees (exact) | 12 |
Acquisitions & public offerings
Acquired by Scipher Medicine Corporation 2026-07 $150.0M
| Acquired | Date | Amount |
|---|---|---|
| Anchiano Therapeutics | 2021-03 |
Radar intelligence
Web history (Wayback)
| Domain | chemomab.com |
|---|
Certificate / subdomain footprint
| Subdomains | 12 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514672625 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2011-09-22 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 2 — annual_report (1), charge (1) |
| Registered address | דבורה הנביאה 121 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2026-05-26 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2025-10-13 | סילוק שעבוד |